You just read:

Armetheon Announces European Medicines Agency's Support for 1000 Patient Single Phase 3 Study prior to MAA Filing for its Novel Oral Anticoagulant Tecarfarin

News provided by

Armetheon, Inc.

Feb 14, 2017, 08:30 ET